Abeona Therapeutics

Abeona Therapeutics

Biotechnology Research

Cleveland, OH 16,295 followers

Working together to find a cure

About us

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Prademagene zamikeracel (pz-cel) is Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa. The Company’s fully integrated cell and gene therapy cGMP manufacturing facility served as the manufacturing site for pz-cel used in its Phase 3 VIITAL™ trial, and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.

Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Cleveland, OH
Type
Public Company
Founded
2015
Specialties
Gene Therapy, Biotechnology, Cell Therapy, Rare Disease, Epidermolysis Bullosa, Pediatric Rare Diseases, and manufacturing

Locations

Employees at Abeona Therapeutics

Updates

Similar pages

Browse jobs

Funding

Abeona Therapeutics 13 total rounds

Last Round

Post IPO equity

US$ 75.0M

See more info on crunchbase